secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2023-03-21T23:59:59+00:00
Accession:  0001171843-23-001783
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Therapeutics reports Q4 net loss $7.8M; cash $19.6M at Dec 31, 2022
------------------------------------------------------------------------

- Net loss for Q4 2022: $7.8M ($0.23/share) vs $5.8M ($0.18) in Q4 2021.
- Full year 2022 net loss $28.0M ($0.83/share) vs $30.2M ($1.16) in 2021.
- Cash and equivalents $19.6M at Dec 31, 2022, down from $38.9M at Dec 31, 2021.
- Cash used in operations FY2022 $18.9M; R&D expense rose to $23.1M from $14.0M.
- Clinical update for agenT-797 in solid tumors to be presented at AACR April 2023; expansion into NSCLC/gastric cancer in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000117184323001783/0001171843-23-001783-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000117184323001783/f8k_032123.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-001783

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer